7 Result: Novartis
Countdown to Earnings: Netflix, GE Aerospace, and Novartis in Spotlight
July 14th, 2025
Several high-profile companies are set to announce their second-quarter 2025 earnings on Thursday, July 17, including: Netflix, Inc. (Nasdaq: NFLX), the global streaming giant, will release its Q2 earnings and business outlook after the market clo. Read more
A Preview: Visa, Novartis, Fiserv, and F5's Earnings In Focus
October 22nd, 2023
On Tuesday, October 24, an array of notable companies is gearing up to unveil their financial results, including: Visa Inc. (NYSE: V), a major player in the global payment technology sector, is poised to disclose its fiscal fourth quarter and full. Read more
Breaking: Novartis Q2 Earnings Beat; Sarconeos Deal Boosts Biophytis
July 18th, 2023
Shares of Novartis AG (NYSE: NVS) experienced a surge in premarket trading as the company surpassed expectations in its second-quarter 2023 financial report. The pharmaceutical giant reported core earnings per share (EPS) of $1.83 and sales . Read more
Bank of America, Novartis, and Morgan Stanley: Earnings Preview
July 16th, 2023
On Tuesday, July 18, several companies are expected to report their financial results, including: Bank of America Corporation (NYSE: BAC), a financial giant, is set to reveal its second-quarter 2023 financial results before the market opens. . Read more
Pharvaris: Potential On-Demand HAE Treatment; Novartis Is To Takeover Chinook Therapeutics
June 12th, 2023
Pharvaris N.V. (Nasdaq: PHVS) released data from their Phase 2 study, RAPIDe-1, evaluating the on-demand treatment of hereditary angioedema (HAE) attacks with PHVS416 (deucrictibant immediate-release capsules). The study showed that treatment with. Read more
Macy's Beats Expectations, Dollar General Falls Short: Revised Downward Forecast - Pharming Group Sells PRV to Novartis
June 01st, 2023
Dollar General Corporation (NYSE: DG), a leading discount retailer, reported first-quarter fiscal 2023 earnings per share (EPS) of $2.34, slightly below the consensus estimate of $2.38. The company acknowledged a more challenging macroeconom. Read more
AVROBIO Sells Cystinosis Therapy Program to Novartis, Stock Surges; Compass Minerals Inks Lithium Supply Deal with Ford; Global-e Online Beats Estimates, Stock Declines
May 22nd, 2023
AVROBIO, Inc. (Nasdaq: AVRO) has made a significant announcement, revealing that it has entered into an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis (NYSE: NVS). . Read more
Want To Find Some News?
News By Industries
Recent Post
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025




Member Login